Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2026, concurrently with the entry by the Company into (1) that certain Transaction Agreement (the “Transaction Agreement”) with Redx Pharma Limited, a private limited company incorporated in England and Wales with registered number 07368089, and (2)…

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Material Modification to Rights of Security Holders. The previously disclosed Certificate will become effective at 12:01 am New York time on Thursday, August 24, 2026, with the Company’s common stock to begin trading on The Nasdaq Stock Market LLC on a split-adjusted basis at market open on August 24, 2026. The common stock will continue to trade under the existing ticker symbol “SKYE.” The new CUSIP number for the common stock following the Reverse Stock Split is 83086J309. Important Informa…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 18, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company’s stockholders’ equity was ($497,307), and therefore, the Company was…

Entry into a Material Definitive Agreement. Transaction Agreement The Transaction On August 14, 2026, Skye Bioscience, Inc., a Nevada corporation (the “ Company ”), entered into a transaction agreement (“ Transaction Agreement ”) with Redx Pharma Limited, a private limited company incorporated in England and Wales with registered number 07368089 (“ Redx ”). The Transaction Agreement provides that, subject to the terms and conditions set forth therein, including the requisite approval of each…

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Changes in Control of Registrant. To the extent required by this Item, the information included in

The excerpt is a standard boilerplate header for Item 5.02 and contains no specific details about any personnel changes.

Material Modification to Rights of Security Holders. The board of directors of the Company approved a reverse stock split of the Company’s authorized, issued and outstanding shares of Common Stock, at a ratio of 1-for-8 (the “ Reverse Stock Split ”). The Company expects that the effective time of the Reverse Stock Split will be on or about 12:01 am New York time on Thursday, August 24, 2026 (the “ Effective Date ”), with the Common Stock trading on the Nasdaq Capital Market (“ Nasdaq ”) on a…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 13, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company’s stockholders’ equity was $9,011,804, and therefore, the Company was not in compl…

The filing is about an option repricing and does not involve any management changes.

Chief Financial Officer — John P. Sharp: The company appointed a new Chief Financial Officer with extensive experience in the biopharmaceutical industry.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 17, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”) had been below the m…

Results of Operations and Financial Conditions. On March 10, 2026 , Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall no…

Chief Financial Officer — Kaitlyn Arsenault: Ms. Arsenault is leaving her position as CFO to pursue new professional opportunities.

Other Events. On February 2, 2026, the Company reported the following interim results from the combination cohort of its Phase 2a extension study: • 19 participants in the combination cohorts completed week 26 and were eligible for the extension study, which continued in a blinded manner for 26 weeks, maintaining their original treatment assignment (10 nimacimab plus semaglutide; 9 placebo plus semaglutide). An additional 22 participants completed week 26 and were either ineligible for the ex…

Entry into a Material Definitive Agreement. On December 18, 2025, Skye Bioscience, Inc. (the “Company”) entered into a Non-exclusive Collaboration and License Agreement (the “Agreement”) with Halozyme, Inc. (“Halozyme”). Under the terms of the Agreement, Halozyme granted the Company a non-exclusive license to Halozyme’s ENHANZE® drug delivery technology for the development of a subcutaneous formulation of nimacimab (such combination, the “Product”). Halozyme will also be the Company’s exclusi…

Results of Operations and Financial Condition. On November 10, 2025, Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release providing a corporate update and reporting its financial results for the period ended September 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 9…

Results of Operations and Financial Condition. On August 7, 2025, Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release providing a corporate update and reporting its financial results for the period ended June 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, sha…

Changes in Registrant's Certifying Accountant Based on information provided by Marcum LLP (“Marcum”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. On June 9, 2025, Marcum resigned as the independent registered public accounting firm of Skye Bioscience, Inc. (the “Company”). On June 9, 2025, the audit committee of the Company's board of directors (the "Board of Directors") engaged CBIZ CPAs as the Company’s independent registered public accou…

Results of Operations and Financial Condition. On May 8, 2025, Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release reporting its financial results for the period ended March 31, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” for purpos…

Results of Operations and Financial Condition. On March 20, 2025, Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release reporting its financial results for the fourth quarter and full year ended December 31, 2024. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not…

The filing describes an amendment to the equity incentive plan, which does not involve any changes in management or executive departures.

Results of Operations and Financial Condition. On November 7, 2024, Skye Bioscience, Inc. (the “Company” or “Skye”) issued a press release reporting its financial results for the period ended September 30, 2024. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed “filed” f…

The company approved salary increases and stock option grants for the CEO and CFO.